1. Date of download: 6/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes JAMA. 2000;284(12):1549-1558. doi:10.1001/jama.284.12.1549 Reproduced with permission from Lefkovits J, Topol EJ. Role of plateletinhibitor agents in coronary artery disease. In: Topol EJ, ed. Textbook of Interventional Cardiology. Philadelphia, Pa: WB SaundersCo; 1999:13. Asterisk indicates low dose vs placebo for PARAGON. Size of squaredata markers indicates sample size. Figure Legend:

2. Date of download: 6/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes JAMA. 2000;284(12):1549-1558. doi:10.1001/jama.284.12.1549 Adapted with permission from Heeschen C, Hamm CW, Goldmann B, etal. Copyright by The Lancet Ltd, 1999. TroponinI was positive if greater than 1.0 µg/L. Figure Legend:

3. Date of download: 6/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes JAMA. 2000;284(12):1549-1558. doi:10.1001/jama.284.12.1549 A reduction was present both during the initial medical managementphase and after percutaneous coronary intervention as well. Adapted with permissionfrom Boersma E, Akkerhuis KM, Theroux P, et al. Figure Legend:

4. Date of download: 6/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes JAMA. 2000;284(12):1549-1558. doi:10.1001/jama.284.12.1549 There is a greater reduction in 30-day death or nonfatal myocardialinfarction with eptifibatide vs placebo when patients are treated early aftersymptom onset. Data from Bhatt DL, Marso SP, Houghtaling P, et al. Figure Legend: